Antoine Thiery-Vuillemin
YOU?
Author Swipe
View article: Treatment recommendations for the systemic pharmacological treatment of systemic sclerosis digital ulcers: Results from the World Scleroderma Foundation Ad Hoc Committee
Treatment recommendations for the systemic pharmacological treatment of systemic sclerosis digital ulcers: Results from the World Scleroderma Foundation Ad Hoc Committee Open
Introduction: Digital ulcers are an important disease manifestation of systemic sclerosis and are associated with significant morbidity. As such, there is an urgent need for the development of evidence-based recommendations to guide clinic…
Development of a conceptual model of early systemic sclerosis (scleroderma) Open
Background Systemic sclerosis (SSc) is a rare connective tissue disorder with heterogeneous manifestations. Two predominant subtypes, limited cutaneous SSc (lcSSc) and diffuse cutaneous SSc (dcSSc), are distinguished based on skin involvem…
View article: ‘Am I doing this right?’ Physician perceptions of the global assessment in clinical trials of systemic sclerosis
‘Am I doing this right?’ Physician perceptions of the global assessment in clinical trials of systemic sclerosis Open
Objectives Physician global assessments (PhyGAs) are commonly performed in randomized controlled trials (RCTs) in SSc. However, there is no single PhyGA applied across RCTs. We performed an exploratory qualitative study to explore percepti…
View article: rechARge: a randomized phase III trial of the androgen receptor ligand-directed degrader, BMS-986365, vs investigator’s choice in patients with mCRPC
rechARge: a randomized phase III trial of the androgen receptor ligand-directed degrader, BMS-986365, vs investigator’s choice in patients with mCRPC Open
There is an ongoing need for efficacious, life-prolonging therapies for males with metastatic castration-resistant prostate cancer (mCRPC). mCRPC that progresses after treatment with androgen receptor pathway inhibitors (ARPIs) may still b…
View article: Recommendations for the local management of digital ulcers in systemic sclerosis: A report from the World Scleroderma Foundation (WSF) ‘Ad hoc committee’
Recommendations for the local management of digital ulcers in systemic sclerosis: A report from the World Scleroderma Foundation (WSF) ‘Ad hoc committee’ Open
Introduction: Digital ulcers (DUs) stand out as one of the most prevalent and clinically meaningful manifestations of systemic sclerosis (SSc) and are associated with significant morbidity. While systemic (pharmacological) therapy is curre…
View article: Evaluation and prescription trends in systemic sclerosis: Report of a survey among Indian rheumatologists
Evaluation and prescription trends in systemic sclerosis: Report of a survey among Indian rheumatologists Open
Objective: This study evaluates assessment and prescription trends in systemic sclerosis across different Indian healthcare settings, with a focus on diagnostic practices such as screening for interstitial lung disease, pulmonary hypertens…
Psychosocial moderators of the association between pain intensity and physical function in people with systemic sclerosis Open
Background: Pain is a prevalent symptom of systemic sclerosis. While previous studies have demonstrated a correlation between higher pain intensity and lower physical function in individuals with systemic sclerosis, the potentially moderat…
Peer mentoring program through a digital platform for people with systemic sclerosis: A feasibility study Open
Objective: People with systemic sclerosis (SSc or scleroderma), a rare chronic autoimmune disease, often face significant physical and emotional challenges. Peer mentoring, where someone with similar lived experiences offers guidance and s…
Pain and Health-related Quality of Life with Biweekly Versus Triweekly Cabazitaxel Schedule in Older Men with Metastatic Castration-resistant Prostate Cancer in the Multicenter, Randomized CABASTY Trial Open
Androgen receptor pathway inhibitors are often preferred to taxane chemotherapy as a treatment of second or subsequent line in older metastatic castration-resistant prostate cancer patients due to more frequent treatment-related toxicities…
Nivolumab in patients with advanced renal cell carcinoma in France: interim results of the observational, real-world WITNESS study Open
Preliminary results of the ongoing WITNESS study confirm the real-world effectiveness and safety of nivolumab monotherapy in previously treated patients with aRCC. Treatment benefits were similar to those observed in the pivotal phase III …
View article: Cost-effectiveness of avelumab first-line maintenance therapy for adult patients with locally advanced or metastatic urothelial carcinoma in France
Cost-effectiveness of avelumab first-line maintenance therapy for adult patients with locally advanced or metastatic urothelial carcinoma in France Open
Background This study evaluated the cost-effectiveness of avelumab first-line (1L) maintenance therapy plus best supportive care (BSC) versus BSC alone for adults with locally advanced or metastatic urothelial carcinoma (la/mUC) that had n…
View article: Carboplatin in metastatic castration-resistant prostate cancer patients with molecular alterations of the DNA damage repair pathway: the PRO-CARBO phase II trial
Carboplatin in metastatic castration-resistant prostate cancer patients with molecular alterations of the DNA damage repair pathway: the PRO-CARBO phase II trial Open
Introduction: DNA damage repair genes are altered in 20–35% of metastatic castration-resistant prostate cancer (mCRPC). Poly-ADP (Adénosine Diphosphate)-ribose polymerase inhibitors (PARPi) showed significant activity for these selected tu…
Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in <i>BRCA1</i> and/or <i>BRCA2</i> in the PROfound Trial Open
Olaparib improved PFS and OS across subgroups of BRCA1/2mut #prostatecancer patients in the PROFOUND phase III trial.
Biweekly vs Triweekly Cabazitaxel in Older Patients With Metastatic Castration-Resistant Prostate Cancer Open
Importance Many patients 65 years or older with metastatic castration-resistant prostate cancer (mCRPC) are denied taxane chemotherapy because this treatment is considered unsuitable. Objective To determine whether biweekly cabazitaxel (CB…
Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Analysis from JAVELIN Bladder 100 by Duration of First-line Chemotherapy and Interval Before Maintenance Open
Avelumab maintenance treatment helped patients with advanced urothelial cancer without disease progression after at least four cycles of prior chemotherapy, and who started maintenance treatment at least 4 wk after chemotherapy, to live lo…
Patient-Reported Outcomes in KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma Open
Background In patients with renal cell carcinoma (RCC) enrolled in the phase III KEYNOTE-564 trial (NCT03142334), disease-free survival (DFS) following nephrectomy was prolonged with use of adjuvant pembrolizumab therapy versus placebo. Pa…
Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defects Open
BACKGROUND: Niraparib is a highly selective poly (adenosine diphosphateribose) polymerase-1 and poly (adenosine diphosphate-ribose) polymerase-2 inhibitor indicated for select patients with ovarian, fallopian tube, and primary peritoneal c…
View article: Supplementary Data from Detection of <i>BRCA1</i>, <i>BRCA2</i>, and <i>ATM</i> Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound
Supplementary Data from Detection of <i>BRCA1</i>, <i>BRCA2</i>, and <i>ATM</i> Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound Open
Supplementary Data from Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound
View article: Supplementary Figure from Detection of <i>BRCA1</i>, <i>BRCA2</i>, and <i>ATM</i> Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound
Supplementary Figure from Detection of <i>BRCA1</i>, <i>BRCA2</i>, and <i>ATM</i> Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound Open
Supplementary Figure from Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound
View article: Supplementary Figure from Detection of <i>BRCA1</i>, <i>BRCA2</i>, and <i>ATM</i> Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound
Supplementary Figure from Detection of <i>BRCA1</i>, <i>BRCA2</i>, and <i>ATM</i> Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound Open
Supplementary Figure from Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound
View article: Supplementary Figure from Detection of <i>BRCA1</i>, <i>BRCA2</i>, and <i>ATM</i> Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound
Supplementary Figure from Detection of <i>BRCA1</i>, <i>BRCA2</i>, and <i>ATM</i> Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound Open
Supplementary Figure from Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound
View article: Data from Detection of <i>BRCA1</i>, <i>BRCA2</i>, and <i>ATM</i> Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound
Data from Detection of <i>BRCA1</i>, <i>BRCA2</i>, and <i>ATM</i> Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound Open
Purpose:Not all patients with metastatic castration-resistant prostate cancer (mCRPC) have sufficient tumor tissue available for multigene molecular testing. Furthermore, samples may fail because of difficulties within the testing procedur…
View article: Supplementary Data from Detection of <i>BRCA1</i>, <i>BRCA2</i>, and <i>ATM</i> Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound
Supplementary Data from Detection of <i>BRCA1</i>, <i>BRCA2</i>, and <i>ATM</i> Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound Open
Supplementary Data from Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound
View article: Supplementary Figure from Detection of <i>BRCA1</i>, <i>BRCA2</i>, and <i>ATM</i> Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound
Supplementary Figure from Detection of <i>BRCA1</i>, <i>BRCA2</i>, and <i>ATM</i> Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound Open
Supplementary Figure from Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound
View article: Data from Detection of <i>BRCA1</i>, <i>BRCA2</i>, and <i>ATM</i> Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound
Data from Detection of <i>BRCA1</i>, <i>BRCA2</i>, and <i>ATM</i> Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound Open
Purpose:Not all patients with metastatic castration-resistant prostate cancer (mCRPC) have sufficient tumor tissue available for multigene molecular testing. Furthermore, samples may fail because of difficulties within the testing procedur…
View article: Supplementary Figure from Detection of <i>BRCA1</i>, <i>BRCA2</i>, and <i>ATM</i> Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound
Supplementary Figure from Detection of <i>BRCA1</i>, <i>BRCA2</i>, and <i>ATM</i> Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound Open
Supplementary Figure from Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound
View article: Supplementary Figure from Detection of <i>BRCA1</i>, <i>BRCA2</i>, and <i>ATM</i> Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound
Supplementary Figure from Detection of <i>BRCA1</i>, <i>BRCA2</i>, and <i>ATM</i> Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound Open
Supplementary Figure from Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound